Jan Lundberg

Jan Lundberg

Chairman of the Research and Development Committee

Dr. Lundberg joined the Board of Ferring in January 2021 as a non-executive director and Chair of the Research and Development Committee. When Dr. Lundberg joined Ferring, he had 18 years’ leadership experience with global organisations such as AstraZeneca and Eli Lilly, and supervised the development of more than 200 drug candidates and 25 approved products across multiple therapeutic areas. He has also served on the boards of several biotechnology companies and on governmental committees in the EU and US. Dr. Lundberg has both a medical and scientific background, and before joining industry was Professor of Pharmacology at the Karolinska Institutet in Sweden. 

This page is not intended for patients or for members of the general public. It is only intended to be used by healthcare professionals.

OK

Cette page n'est pas destinée aux patients ou au grand public. Il est uniquement destiné à être utilisé par des professionnels de santé.

OK

Ik bevestig dat ik een professionele zorgverlener ben of een zakelijke relatie heb met Ferring Pharmaceuticals

OK

Ez az oldal nem betegeknek, vagy nagyközönségnek szól. Az oldalt kizárólag egészségügyi szakemberek használhatják.

OK

Ta strona nie jest przeznaczona dla pacjentów ani dla ogółu odwiedzających. Ta strona stworzona jest dla pracowników sektora ochrony zdrowia.

OK

Эта страница не предназначена для пациентов или для широкой публики. Она предназначена только для медицинских работников.

OK